Patients with plaque psoriasis who underwent laser treatment did not show evidence of subsequent koebnerization, according to recent research.
“Koebnerization did not occur on the face, neck, or scalp in patients with plaque psoriasis who underwent laser treatment, irrespective of the severity of their psoriasis and medication they were receiving at the time of their procedure,” Suzanne M. Sachsman, MD, from the division of dermatology at the University of California, Los Angeles School of Medicine, and colleagues wrote. “The use of laser therapy devices seemed well-tolerated and safe in the small subset of patients on biologic and other systemic therapies for psoriasis. However, the risk of koebnerization should be explained to patients with plaque psoriasis who wish to undergo laser therapy.”
Sachsman and colleagues evaluated the incidence of koebnerization in 38 patients with plaque psoriasis who underwent laser treatment. The researchers studied patient characteristics, psoriasis duration, psoriasis severity, psoriasis treatment at baseline, number of laser treatment sessions, location of laser treatment sessions as well as laser modality and settings.
Of the patients who received treatment, 14 patients were receiving biological agents, seven were taking oral medications, and three patients were taking combination therapy, the researchers wrote. Sachsman and colleagues found that no patients had evidence of koebnerization after treatment; further, no patients had evidence of scarring, delayed healing or skin infections regardless of psoriasis therapy.
“As a general rule, biologic agents are generally discontinued before and after major surgery due to the potential for increased infections and delayed wound healing,” the researchers wrote. “However, there is general discordance in the literature on whether there is a true association between increased infections when biologic agents are not withheld before and after major surgery. Recent evidence suggests continuation of these therapies during minor surgical procedures is safe.” – by Jeff Craven
Disclosure: Sachsman reports no relevant financial disclosures. Please see the full study for a list of all other authors’ relevant financial disclosures.